South Korea
# |
Name |
EBIT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
31.79%
|
Dec. 31, 2023 | USD 119.86 | -2.20% |
|
South Korea |
|
2 |
23.83%
|
Dec. 31, 2023 | USD 11.00 | -3.03% |
|
South Korea |
|
3 |
10.34%
|
Dec. 31, 2023 | USD 54.68 | -7.62% |
|
South Korea |
|
4 |
6.84%
|
Dec. 31, 2023 | USD 11.62 | -0.90% |
|
South Korea |
|
5 |
-0.76%
|
Dec. 31, 2023 | USD 25.27 | 1.91% |
|
South Korea |
|
6 |
-3.00%
|
Dec. 31, 2023 | USD 240.05 | -5.25% |
|
South Korea |
|
7 |
-10.57%
|
Dec. 31, 2023 | USD 70.28 | -5.55% |
|
South Korea |
|
8 |
-12.21%
|
Dec. 31, 2023 | USD 1.01 | -3.22% |
|
South Korea |
|
9 |
-19.51%
|
Dec. 31, 2023 | USD 11.83 | -21.52% |
|
South Korea |
|
10 |
-80.74%
|
Dec. 31, 2023 | USD 10.77 | -3.15% |
|
South Korea |
|
11 |
-190.22%
|
Dec. 31, 2023 | USD 1.42 | -2.25% |
|
South Korea |
|
12 |
-465.15%
|
Dec. 31, 2023 | USD 64.97 | -2.50% |
|
South Korea |
|
13 |
-643.86%
|
Dec. 31, 2023 | USD 17.88 | -1.83% |
|
South Korea |
|
14 |
-749.28%
|
Dec. 31, 2023 | USD 1.23 | -3.88% |
|
South Korea |
|
15 |
-942.80%
|
Dec. 31, 2023 | USD 1.61 | -1.19% |
|
South Korea |
|
16 |
-1,037.12%
|
Dec. 31, 2023 | USD 3.04 | -3.81% |
|
South Korea |
The Clinical Trials company in South Korea with the highest EBIT Margin is Celltrion, Inc. (KSE: 068270.KS) at 31.79%.
The Clinical Trials company in South Korea with the lowest EBIT Margin is Genexine, Inc. (KOSDAQ: 095700.KQ) at -1,037.12%.
The top 10 Clinical Trials companies in South Korea by EBIT Margin are Celltrion, Inc., Boditech Med Inc., ST Pharm Co.,Ltd., Samjin Pharmaceuticals Co., Ltd., ABL Bio Inc., ALTEOGEN Inc., SK Biopharmaceuticals Co., Ltd., Enzychem Lifesciences Corporation, Anterogen.Co.,Ltd. and OliX Pharmaceuticals,Inc.
The bottom 10 Clinical Trials companies in South Korea by EBIT Margin are Genexine, Inc., CrystalGenomics, Inc., Gencurix Inc., Oscotec Inc., Peptron, Inc., GeneOne Life Science, Inc., OliX Pharmaceuticals,Inc, Anterogen.Co.,Ltd., Enzychem Lifesciences Corporation and SK Biopharmaceuticals Co., Ltd..